CSL Limited - Asset Resilience Ratio
CSL Limited (CSJ) has an Asset Resilience Ratio of 0.03% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2021)
This chart shows how CSL Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CSL Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €4.80 Million | 0.03% |
| Total Liquid Assets | €4.80 Million | 0.03% |
Asset Resilience Insights
- Limited Liquidity: CSL Limited maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
CSL Limited Industry Peers by Asset Resilience Ratio
Compare CSL Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
ACRO Biomedical Co., Ltd.
TWO:6748 |
Biotechnology | 60.44% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
Annual Asset Resilience Ratio for CSL Limited (2014–2021)
The table below shows the annual Asset Resilience Ratio data for CSL Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-06-30 | 0.03% | €4.80 Million | €18.16 Billion | +0.01pp |
| 2020-06-30 | 0.02% | €4.81 Million | €22.53 Billion | +0.02pp |
| 2019-06-30 | 0.00% | €570.37K | €17.56 Billion | -0.01pp |
| 2018-06-30 | 0.01% | €2.16 Million | €14.58 Billion | -0.04pp |
| 2017-06-30 | 0.06% | €6.76 Million | €11.86 Billion | +0.05pp |
| 2016-06-30 | 0.01% | €807.97K | €10.18 Billion | -0.03pp |
| 2015-06-30 | 0.04% | €2.60 Million | €6.40 Billion | +0.04pp |
| 2014-06-30 | 0.00% | €300.00K | €6.28 Billion | -- |
About CSL Limited
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more